95 related articles for article (PubMed ID: 25725586)
1. Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancer.
Koo DH; Lee HJ; Ahn JH; Yoon DH; Kim SB; Gong G; Son BH; Ahn SH; Jung KH
Tumour Biol; 2015 Aug; 36(8):5865-71. PubMed ID: 25725586
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial.
Pusztai L; Jeong JH; Gong Y; Ross JS; Kim C; Paik S; Rouzier R; Andre F; Hortobagyi GN; Wolmark N; Symmans WF
J Clin Oncol; 2009 Sep; 27(26):4287-92. PubMed ID: 19667268
[TBL] [Abstract][Full Text] [Related]
3. Combined analysis of PTEN, HER2, and hormone receptors status: remodeling breast cancer risk profiling.
Sajjadi E; Venetis K; Piciotti R; Gambini D; Blundo C; Runza L; Ferrero S; Guerini-Rocco E; Fusco N
BMC Cancer; 2021 Oct; 21(1):1152. PubMed ID: 34706703
[TBL] [Abstract][Full Text] [Related]
4. Immunoexpression of HER2 pathway related markers in HER2 invasive breast carcinomas treated with trastuzumab.
Franco AFDV; Malinverni ACM; Waitzberg AFL
Pathol Res Pract; 2023 Dec; 252():154917. PubMed ID: 37977031
[TBL] [Abstract][Full Text] [Related]
5. How relevant is hormone receptor status in the context of outcome to HER2-positive breast cancer?
Norton N; Perez EA
Breast Cancer Res; 2013 Jan; 15(1):101. PubMed ID: 23316883
[TBL] [Abstract][Full Text] [Related]
6. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer.
Rouzier R; Rajan R; Wagner P; Hess KR; Gold DL; Stec J; Ayers M; Ross JS; Zhang P; Buchholz TA; Kuerer H; Green M; Arun B; Hortobagyi GN; Symmans WF; Pusztai L
Proc Natl Acad Sci U S A; 2005 Jun; 102(23):8315-20. PubMed ID: 15914550
[TBL] [Abstract][Full Text] [Related]
7. Partial PTEN deletion is linked to poor prognosis in breast cancer.
Lebok P; Kopperschmidt V; Kluth M; Hube-Magg C; Özden C; B T; Hussein K; Mittenzwei A; Lebeau A; Witzel I; Wölber L; Mahner S; Jänicke F; Geist S; Paluchowski P; Wilke C; Heilenkötter U; Simon R; Sauter G; Terracciano L; Krech R; von d Assen A; Müller V; Burandt E
BMC Cancer; 2015 Dec; 15():963. PubMed ID: 26672755
[TBL] [Abstract][Full Text] [Related]
8. Anticancer Activity of HER2-targeting CPP-PTEN-THP Chimeric Proteins.
Pioquinto-Avila E; González-Cruz AO; Solís-Estrada J; Hernández-Juarez J; Balderas-Rentería I; Villa-Cedillo SA; Pérez-Trujillo JJ; Arredondo-Espinoza E
Anticancer Res; 2024 Jun; 44(6):2567-2575. PubMed ID: 38821612
[TBL] [Abstract][Full Text] [Related]
9. Molecular and serological biomarkers to predict trastuzumab responsiveness in HER-2 positive breast cancer.
Abdullah N; Al-Mansouri L; Ali N; Hadi NR
J Med Life; 2023 Nov; 16(11):1633-1638. PubMed ID: 38406785
[TBL] [Abstract][Full Text] [Related]
10. Quantitative assessment of HER2 amplification in HER2-positive breast cancer: its association with clinical outcomes.
Xuan Q; Ji H; Tao X; Xu Y; Zhang Q
Breast Cancer Res Treat; 2015 Apr; 150(3):581-8. PubMed ID: 25762478
[TBL] [Abstract][Full Text] [Related]
11. β2-AR signaling controls trastuzumab resistance-dependent pathway.
Liu D; Yang Z; Wang T; Yang Z; Chen H; Hu Y; Hu C; Guo L; Deng Q; Liu Y; Yu M; Shi M; Du N; Guo N
Oncogene; 2016 Jan; 35(1):47-58. PubMed ID: 25798840
[TBL] [Abstract][Full Text] [Related]
12. Predictive and prognostic significance of p27, Akt, PTEN and PI3K expression in HER2-positive metastatic breast cancer.
Okutur K; Bassulu N; Dalar L; Aydin K; Bozkurt M; Pilanci KN; Dogusoy GB; Tecimer C; Mandel NM; Demir G
Asian Pac J Cancer Prev; 2015; 16(7):2645-51. PubMed ID: 25854340
[TBL] [Abstract][Full Text] [Related]
13. Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer.
Boyle FM; Smith IE; O'Shaughnessy J; Ejlertsen B; Buzdar AU; Fumoleau P; Gradishar W; Martin M; Moy B; Piccart-Gebhart M; Pritchard KI; Lindquist D; Amonkar M; Huang Y; Rappold E; Williams LS; Wang-Silvanto J; Kaneko T; Finkelstein DM; Goss PE;
Eur J Cancer; 2015 Apr; 51(6):685-96. PubMed ID: 25752740
[TBL] [Abstract][Full Text] [Related]
14. Patients with HER2-positive early breast cancer receiving adjuvant trastuzumab: clinicopathological features, efficacy, and factors affecting survival.
Ulas A; Kos T; Avci N; Cubukcu E; Olmez OF; Bulut N; Degirmenci M
Asian Pac J Cancer Prev; 2015; 16(4):1643-9. PubMed ID: 25743846
[TBL] [Abstract][Full Text] [Related]
15. Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.
Gelmon KA; Boyle FM; Kaufman B; Huntsman DG; Manikhas A; Di Leo A; Martin M; Schwartzberg LS; Lemieux J; Aparicio S; Shepherd LE; Dent S; Ellard SL; Tonkin K; Pritchard KI; Whelan TJ; Nomikos D; Nusch A; Coleman RE; Mukai H; Tjulandin S; Khasanov R; Rizel S; Connor AP; Santillana SL; Chapman JA; Parulekar WR
J Clin Oncol; 2015 May; 33(14):1574-83. PubMed ID: 25779558
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic complete response in patients with early stage HER2-positive breast cancer: a meta-analysis of randomized prospective clinical trials.
Hicks M; Macrae ER; Abdel-Rasoul M; Layman R; Friedman S; Querry J; Lustberg M; Ramaswamy B; Mrozek E; Shapiro C; Wesolowski R
Oncologist; 2015 Apr; 20(4):337-43. PubMed ID: 25732265
[TBL] [Abstract][Full Text] [Related]
17. [Trastuzumab emtansine (Kadcyla(®)) approval in HER2-positive metastatic breast cancers].
Guerin M; Sabatier R; Gonçalves A
Bull Cancer; 2015 Apr; 102(4):390-7. PubMed ID: 25790739
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of microtubule-associated protein Tau in patients with recurrent and metastatic breast cancer treated with taxane-containing palliative chemotherapy.
Zhou J; Qian S; Li H; He W; Tan X; Zhang Q; Han G; Chen G; Luo R
Tumour Biol; 2015 May; 36(5):3941-7. PubMed ID: 25773385
[TBL] [Abstract][Full Text] [Related]
19. Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant basal-HER2 subtype of breast cancer.
Martin-Castillo B; Lopez-Bonet E; Buxó M; Dorca J; Tuca-Rodríguez F; Ruano MA; Colomer R; Menendez JA
Oncotarget; 2015 Mar; 6(9):7104-22. PubMed ID: 25742793
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of dose dense doxorubicin and cyclophosphamide followed by paclitaxel versus conventional dose doxorubicin, cyclophosphamide followed by paclitaxel or docetaxel in patients with node-positive breast cancer.
Yazilitas D; Sendur MA; Karaca H; Ozdemir N; Aksoy S; Berk V; Yazici O; Ozturk B; Ozkan M; Zengin N; Altundag K
Asian Pac J Cancer Prev; 2015; 16(4):1471-7. PubMed ID: 25743817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
